Filing Flows › Vistagen Therapeutics (VTGN) › Q4 FY26 › vs Q3 FY26
Vistagen Therapeutics (VTGN) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Vistagen Therapeutics's revenue rose $162K (+53%) from $303K in Q3 FY26 to $465K in Q4 FY26.
Vistagen Therapeutics, Q4 FY26: revenue $465K, net loss $16.3M, operating cash flow −$16.2M. The chart draws each line against Q3 FY26, the increases inside each band.
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $465K | $303K | $162K | +53% |
| Other income, net | $450K | $647K | −$197K | -30% |
| Net loss | $16.3M | $18.9M | −$2.6M | -14% |
| Costs & expenses | $17.2M | $19.8M | −$2.7M | -13% |
| Operating costs | $17.2M | $19.8M | −$2.7M | -13% |
| Income tax | $7K | $0 | $7K | — |
| Research & development | $13.1M | $14.2M | −$1.2M | -8% |
| General & admin | $4.1M | $5.6M | −$1.5M | -27% |
| Operating cash sources | $17.1M | $18.8M | −$1.6M | -9% |
| Depreciation & amortization | $52K | $54K | −$2K | -4% |
| Share-based compensation | $889K | $1.1M | −$207K | -19% |
| Cash used in operations | $16.2M | $17.6M | −$1.4M | -8% |
| Net loss absorbed | $16.3M | $18.9M | −$2.6M | -14% |
| Working capital & other | $867K | −$118K | $985K | — |
Questions
How much did Vistagen Therapeutics's revenue grow quarter over quarter in Q4 FY26?
Vistagen Therapeutics's revenue rose $162K (+53%) from $303K in Q3 FY26 to $465K in Q4 FY26.